Abstract
Due to the promising results of recent trials in the treatment of metastatic renal cell cancer (mRCC) multi-drug regimens combining immunotherapy and targeted therapy in the first line are increasingly recognized. The combinations are already included in international clinical guidelines as preferred treatment options for patients with mRCC. In particular, combination of lenvatinib and pembrolizumab demonstrated high efficacy in terms of achieving a complete response, progression-free survival with a manageable toxicity profile. All adverse events on this therapy are predictable and quite well controlled. We report on our own experience of using lenvatinib plus pembrolizumab combination therapy on the example of two clinical cases of patients with intermediate prognosis mRCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
